16 known cases. View patent page →
Hatch-Waxman ANDA patent infringement action in the District of New Jersey. The multi-patent Xyrem complaint included US 7,668,730 and also asserted the '059, '988, '182, and '963 patents. The case was resolved short of trial and closed.
Federal Circuit appeal from the PTAB IPR decision on U.S. 8,589,182. The court affirmed, holding the FDA Advisory Committee materials were a publicly accessible printed publication and proper prior art; the decision disposed of the family patents together.
Cover Business Method review petition filed by Par, Roxane, and Amneal against Jazz Pharmaceuticals. The Board denied institution on January 13, 2015.
Inter partes review filed by Par Pharmaceutical, Inc. (et al.) against Jazz Pharmaceuticals. The Board instituted review and issued a final written decision on July 27, 2016 holding all claims of U.S. 7,895,059 unpatentable.
Inter partes review petition filed by Coalition for Affordable Drugs III LLC against Jazz Pharmaceuticals. The Board denied institution on October 15, 2015.
Inter partes review petition filed by Amneal Pharmaceuticals LLC against Jazz Pharmaceuticals. It was instituted with joinder and terminated on July 27, 2016, resolved by the final written decision in IPR2015-00548.
Inter partes review petition filed by Wockhardt Bio AG (et al.) against Jazz Pharmaceuticals. After joinder, Wockhardt terminated May 5, 2016, and the proceeding terminated July 27, 2016 by the final written decision in IPR2015-00548.
Hatch-Waxman ANDA suit filed by Jazz Pharmaceuticals against Roxane Laboratories concerning U.S. 7,895,059. The case was consolidated with lead action 2:10-cv-06108 and settled in April 2017.
Hatch-Waxman ANDA suit filed by Jazz Pharmaceuticals against Par Pharmaceutical. The case was consolidated under 2:13-cv-0391 and settled on January 9, 2018.
Hatch-Waxman ANDA suit listed as related litigation involving Jazz Pharmaceuticals and Wockhardt Bio AG. Wockhardt's paragraph IV notices were dated June 5, 2015 and November 24, 2015.
Antitrust/pay-for-delay class action listing U.S. 7,895,059 among the Orange Book patents at issue. Filed June 18, 2020.
Antitrust/pay-for-delay class action listing U.S. 7,895,059 among the Orange Book patents at issue. The case was terminated July 22, 2020.
Antitrust/pay-for-delay class action listing U.S. 7,895,059 among the Orange Book patents and expiries at issue.
Antitrust/pay-for-delay class action listing U.S. 7,895,059 among the listed patents; consolidated in the Xyrem antitrust proceedings.
Lead consolidated Hatch-Waxman action over Xyrem sodium oxybate. The ’506 patent was among the original patents-in-suit, along with the ’431, ’889, ’219, ’059, and the ’730 family. Resolved by settlement with no final judgment on the ’506 patent.
Jazz Pharmaceuticals sued Ranbaxy Laboratories and Ranbaxy Inc. in a Hatch-Waxman ANDA patent infringement action over generic sodium oxybate referencing Xyrem. The complaint asserted multiple patents including U.S. Patent No. 8,461,203. The case was consolidated for all purposes into Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 13-391-ES-JAD, and administratively terminated.